Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection
Hematological Oncology · 2023-12 · 41 (5) · 904-911
DOI: 10.1002/hon.3206 ↗At a glance
Journal article in Hematological Oncology, published online on 2023-07-15. Written by Zeno Pasquini and 16 co-authors. Institution: Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Major MEDLINE topics: Ritonavir, COVID-19. Cited 44 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID‐19‐associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection. We report a case series of adult patients with B cell malignancies and/or undergoing B cell targeting therapies with persisting SARS‐CoV‐2 infection and treated with a combination antiviral therapy of remdesivir and nirmatrelvir/ritonavir, in three Italian tertiary academic hospitals. A total of 14 patients with impaired adaptive humoral immunity and prolonged SARS‐CoV‐2 infection were treated with the dual antiviral therapy. The median age was 60 (IQR 56–68) years, and 11 were male. Twelve patients had B cell lymphoma, one patient had chronic lymphocytic leukemia and one patient had multiple sclerosis. Thirteen out of 14 patients had received prior B cell‐targeting therapies, consisting of anti‐CD20 monoclonal antibodies in 11 patients, and chimeric antigen receptor T therapy in 2 patients. The median time between diagnosis and therapy start was 42.0 (IQR 35–46) days. Seven patients had mild, 6 moderate and one severe disease. Nine patients had signs of interstitial pneumonitis on chest computed tomography scans before treatment. The median duration of nirmatrelvir/ritonavir and remdesivir combination therapy was 10 days. All patients showed resolution of COVID‐19‐related symptoms after a median of 6 (IQR 4–11) days and viral clearance after 9 (IQR 5–11) days. Combination therapy with remdesivir and nirmatrelvir/ritonavir is a promising treatment option for persistent COVID‐19 in immunocompromized patients with humoral immunity impairment, worthy of prospective comparative trials.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Institute of Hematology "L. e A. Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome, Italy.
- Infectious Disease Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
ORCID profiles: Zeno Pasquini, Pierluigi Zinzani
Cite
APA
Pasquini, Z., Toschi, A., Casadei, B., Pellegrini, C., D'Abramo, A., Vita, S., Beccacece, A., Bussini, L., Chionsini, M. C., Dentale, N., Cantiani, A., Lazzarotto, T., Bartoletti, M., Nicastri, E., Zinzani, P., Giannella, M., & Viale, P. (2023). Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection. Hematological Oncology, 41(5), 904-911. https://doi.org/10.1002/hon.3206
Vancouver
Pasquini Z, Toschi A, Casadei B, Pellegrini C, D'Abramo A, Vita S, et al. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection. Hematological Oncology. 2023;41(5):904-911. doi:10.1002/hon.3206
BibTeX
@article{Pasquini2023,
author = {Pasquini, Zeno and Toschi, Alice and Casadei, Beatrice and Pellegrini, Cinzia and D'Abramo, Alessandra and Vita, Serena and Beccacece, Alessia and Bussini, Linda and Chionsini, Maria Clara and Dentale, Nicola and Cantiani, Alessia and Lazzarotto, Tiziana and Bartoletti, Michele and Nicastri, Emanuele and Zinzani, Pierluigi and Giannella, Maddalena and Viale, Pierluigi},
title = {Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {5},
pages = {904--911},
doi = {10.1002/hon.3206}
}
EUVIMED